{
    "score": [
        0.5555555555555556
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "teligent & intellipharmaceutics intl head to head contrast ."
    ],
    "id": "795609.train",
    "article": [
        "teligent and intellipharmaceutics intl are both small-cap healthcare companies , but which is the superior investment ? we will contrast the two companies based on the strength of their risk , institutional ownership , valuation , profitability , analyst recommendations , earnings and dividends . profitabilitythis table compares teligent and intellipharmaceutics intl 's net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetsteligent-16.95 % -6.51 % -1.92 % intellipharmaceutics intl-205.34 % -2,062.11 % -135.25 rnings & valuationthis table compares teligent and intellipharmaceutics intl 's gross revenue , earnings per share and valuation . ",
        "gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratioteligent $ 66.88 million3 .04 - $ 11.98 million-17.32 intellipharmaceutics intl $ 2.25 million11 .19 - $ 10.14 million-2.38 intellipharmaceutics intl has lower revenue , but higher earnings than teligent . teligent is trading at a lower price-to-earnings ratio than intellipharmaceutics intl , indicating that it is currently the more affordable of the two stocks . analyst recommendationsthis is a summary of recent ratings and recommmendations for teligent and intellipharmaceutics intl , as reported by marketbeat . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scoreteligent02102 .33 intellipharmaceutics intl02102 .33 teligent currently has a consensus target price of $ 7.00 , indicating a potential upside of 83.73 % . ",
        "intellipharmaceutics intl has a consensus target price of $ 2.37 , indicating a potential upside of 192.18 % . given intellipharmaceutics intl 's higher probable upside , analysts plainly believe intellipharmaceutics intl is more favorable than teligent . volatility & riskteligent has a beta of 1.34 , suggesting that its share price is 34 % more volatile than the s&p 500 . comparatively , intellipharmaceutics intl has a beta of 0.99 , suggesting that its share price is 1 % less volatile than the s&p 500 . insider & institutional ownership70 .8 % of teligent shares are held by institutional investors . ",
        "comparatively , 3.8 % of intellipharmaceutics intl shares are held by institutional investors . 22.6 % of teligent shares are held by company insiders . strong institutional ownership is an indication that endowments , large money managers and hedge funds believe a stock will outperform the market over the long term . summaryteligent beats intellipharmaceutics intl on 8 of the 12 factors compared between the two stocks . about teligentteligent , inc. . is a specialty generic pharmaceutical company . under the company 's own label , it markets and sells generic injectable pharmaceutical products in the united states and canada . ",
        "in the united states it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products , as of december 31 , 2016 . it provides development , formulation and manufacturing services to the pharmaceutical , over-the-counter and cosmetic industries . it focuses on developing , manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical , injectable , complex and ophthalmic dosage forms , and managing its contract manufacturing and formulation services business . its pipeline included 34 abbreviated new drug application filed with the united states food and drug administration for additional pharmaceutical products , as of december 31 , 2016 . ",
        "about intellipharmaceutics intlintellipharmaceutics international inc is a canada-based pharmaceutical company engaged in the research , development and manufacture of controlled-release and targeted-release oral solid dosage drugs . its hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals . based on this technology platform , it has developed various drug delivery systems and a pipeline of products , and product candidates in various stages of development , in therapeutic areas that include neurology and cardiovascular . its pipeline of products includes rexista oxycodone , regabatin xr , generic focalin xr , generic effexor xr , generic protonix , generic glucophage xr , generic seroquel xr , generic lamictal xr , generic keppra xr , generic pristiq and generic ranexa . ",
        "its generic product candidates also include trazodone hydrochloride extended-release tablets and carvedilol phosphate extended-release capsules . receive news & ratings for teligent daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for teligent and related companies with marketbeat . com 's free daily email newsletter .   "
    ]
}